세포 치료용 인체 원료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cell Therapy Human Raw Materials Market size is expected to reach USD 32.21 Billion in 2034 from USD 5.04 Billion (2025) growing at a CAGR of 22.89% during 2026-2034.

The global cell therapy human raw materials market is witnessing strong growth driven by increasing research and commercialization of advanced cell-based therapies. Human-derived raw materials such as serum, growth factors, and cell culture media are essential in manufacturing cell therapies. Rising investments in regenerative medicine and immunotherapy are significantly boosting demand.

Major growth drivers include expanding clinical trials, increasing regulatory approvals for cell therapies, and rising focus on personalized medicine. Biopharmaceutical companies are strengthening supply chains to ensure high-quality and compliant raw materials. Growing collaborations between research institutions and industry players are further supporting market development.

In the future, advancements in manufacturing technologies and increasing commercialization of CAR-T and stem cell therapies will create significant opportunities. As demand for innovative biologics rises, the cell therapy human raw materials market is expected to expand steadily across global healthcare sectors.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Cell Culture Media
• Cell Culture Sera
• Cell Culture Supplements
• Reagents & Buffers
• Other Raw Materials

By End-Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Merck KGaA, Actylis, ACROBiosystems, STEMCELL Technologies Inc, Grifols SA, Charles River Laboratories International Inc, RoosterBio Inc, PromoCell GmbH, Danaher Corporation, BioIVT LLC, GeminiBio Gemini Bioproducts LLC, Akron Biotech, AllCells LLC, CGT Global
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Cell Culture Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Culture Sera Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Culture Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents & Buffers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Raw Materials Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Biopharmaceutical & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CROs & CMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Academic & Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL THERAPY HUMAN RAW MATERIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Thermo Fisher Scientific Inc
  • 8.2.2 Merck KGaA
  • 8.2.3 Actylis
  • 8.2.4 ACROBiosystems
  • 8.2.5 STEMCELL Technologies Inc
  • 8.2.6 Grifols S.A
  • 8.2.7 Charles River Laboratories International Inc
  • 8.2.8 RoosterBio Inc
  • 8.2.9 PromoCell GmbH
  • 8.2.10 Danaher Corporation
  • 8.2.11 BioIVT LLC
  • 8.2.12 GeminiBio (Gemini Bioproducts LLC)
  • 8.2.13 Akron Biotech
  • 8.2.14 AllCells LLC
  • 8.2.15 CGT Global